Vijay P. Kale

Employment

• Bristol Myers Squibb Principal Scientist
  2022 - Present
• Amgen Inc San Francisco Project Toxicologist
  2020 - 2022
• Battelle Memorial Institute Toxicology Study Director and Project Toxicologist
  2015 - 2020
• Zydus Research Center Toxicology Study Director, Project Toxicologist, Clinical Pathologist
  2004 - 2015

Education

• Penn State College of Medicine PhD
  2010 - 2015
• S. D. Agricultural University M.V.Sc.
  2002 - 2004
• Bombay Veterinary Science College B.V.Sc. & A.H.
  1997 - 2002

Projects & Funding

Projects & funding information is unavailable.

Publications (19)

• Points to consider regarding the use and implementation of virtual controls in nonclinical general toxicology studies
  Regulatory Toxicology and Pharmacology 2024 DOI: 10.1016/j.yrtph.2024.105632
  +Save
• Characterization of Anticancer Effects of the Analogs of DJ4, a Novel Selective Inhibitor of ROCK and MRCK Kinases
  Pharmaceuticals 2023 DOI: 10.3390/ph16081060
  +Save
• Practical Considerations in Determining Adversity and the No-Observed-Adverse-Effect-Level (NOAEL) in Nonclinical Safety Studies: Challenges, Perspectives and Case Studies
  International Journal of Toxicology 2022 DOI: 10.1177/10915818211073047
  +Save
• Evaluation of chronic toxicity of cyclocreatine in beagle dogs after oral gavage administration for up to 23 weeks.
  Toxicology and applied pharmacology 2021 DOI: 10.1016/j.taap.2021.115680
  +Save
• Advances in Cancer Signal Transduction and Therapy
  BENTHAM SCIENCE PUBLISHERS 2020 DOI: 10.2174/97898114581181200101
  +Save
• Evaluation of chronic toxicity of cyclocreatine, a creatine analog, in Sprague Dawley rat after oral gavage administration for up to 26 weeks.
  Regulatory toxicology and pharmacology : RTP 2020 DOI: 10.1016/j.yrtph.2020.104750
  +Save
• Old drugs, new uses: Drug repurposing in hematological malignancies.
  Seminars in cancer biology 2020 DOI: 10.1016/j.semcancer.2020.03.005
  +Save
• Preclinical toxicity evaluation of JD5037, a peripherally restricted CB1 receptor inverse agonist, in rats and dogs for treatment of nonalcoholic steatohepatitis.
  Regulatory toxicology and pharmacology : RTP 2019 DOI: 10.1016/j.yrtph.2019.104483
  +Save
• Role of Gambogic Acid in Chemosensitization of Cancer
  Role of Nutraceuticals in Chemoresistance to Cancer 2018 DOI: 10.1016/b978-0-12-812373-7.00008-5
  +Save
• Targeting ion channels for cancer therapy by repurposing the approved drugs.
  Biochimica et biophysica acta 2015 DOI: 10.1016/j.bbamem.2015.03.034
  +Save